Entering text into the input field will update the search result below

Pieris Pharmaceuticals: 060 Data Looks Great, What Gives?

Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.


  • Shares of PIRS have shed 1/3rd of their value over the past five days.
  • In the ROTY model account, we took partial profits near the peak and sold the remaining 3/4 position for only a slight gain (disappointing outcome).
  • 060 data provided major validation for Pieris' anticalin platform, yet the reaction was a headscratcher.
  • Biotech sector as reflected in XBI shed over 7.5% this week, which certainly didn't help.
  • AstraZeneca is speeding forward in a phase 2 study and PIRS remains a platform tech play to keep on readers' radar.

Pieris Pharmaceuticals (PIRS) was a name we held in ROTY's model account due to enthusiasm for multi-dose PRS-060 results. Specifically, our thesis for this name was based on potential of the Anticalin drug class with multiple irons in the fire and management's prudent manner of managing risk yet retaining significant economics through carefully crafted partnerships. Near term thesis was predicated on presentation of results for the multiple ascending dose study of PRS-060 (focusing on FeNo reduction versus placebo, taking into account that dupilumab was approved in the EU using that endpoint). An inhaled IL-4Rα program would offer several points of differentiation versus approved therapy (ie. convenience, decreased cost) and positive data would likely reflect well on the potential of Pieris' other novel inhaled programs and allow for choosing the correct dose for phase 2a program. We noted here we didn't need much to move the needle since enterprise value was just $90 million or so. 

On September 19th, we sold 1/4 of our position for a 35% ish profit (trades occur at day's closing price, allowing for members to often get better cost averages as they act earlier in the day). This past Thursday, we sold the remaining position for just a 5% profit (quite the disappointing outcome).

Data by YCharts

Full data came out in the abstract for ERS presentation for PRS-060. It looked quite good with impressive FeNO reductions, proving the program is well on track to progress into phase 2 and beyond.


I liked how ROTY member Josh.Bio described it regarding removing PIRS as his Idea Lab submission (high conviction stock picks from members), stating that slow development timelines are overshadowing validation of the platform. Another member, playing devil's advocate, noted that 060 looks like a $1B + drug as long as there aren't any unexpected side effects such as the respiratory infections that become an issue. PIRS could likely go with the low dose, which again for asthma patients would provide a cost effective alternative to dupilumab (uses 400 mg SC once then 200mg q2weeks I believe).


I think the anticalin platform received major validation with this readout and it's always possible that stock bounces back as management provides further clarification. As this was an early-stage study, perhaps market reaction just reflects on the significant amount of headway that still needs to be made in the clinic. 

AstraZeneca is speeding this one into a phase 2 study and that should be seen as a sign of confidence in the program. For our purposes, I'll be keeping an eye on their progress to revisit at a later date.

Look forward to others' thoughts on initial data, the stock's chance of rebounding and implications going forward. Have a great weekend!


For readers who wish to take their biotech investing/trading efforts to the next level, I invite you to try out the 2 Week Free Trial in ROTY (Runners of the Year).

ROTY is a tight knit 500+ member community of experienced biotech investors, profitable traders, industry veterans and novices. Our active Live Chat is characterized by generous sharing of due diligence, knowledge and continuous improvement.

Subscription includes access to our market-beating model account, Idea Lab, Cheat Sheet, Catalyst Tracker and much more! You can check out our reviews here.

Disclaimer: Commentary presented is NOT individualized investment advice. Opinions offered here are NOT personalized recommendations. Readers are expected to do their own due diligence or consult an investment professional if needed prior to making trades. Strategies discussed should not be mistaken for recommendations, and past performance may not be indicative of future results. Although I do my best to present factual research, I do not in any way guarantee the accuracy of the information I post. I reserve the right to make investment decisions on behalf of myself and affiliates regarding any security without notification except where it is required by law. Keep in mind that any opinion or position disclosed on this platform is subject to change at any moment as the thesis evolves. Investing in common stock can result in partial or total loss of capital. In other words, readers are expected to form their own trading plan, do their own research and take responsibility for their own actions. If they are not able or willing to do so, better to buy index funds or find a thoroughly vetted fee-only financial advisor to handle your account

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.